S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
NASDAQ:PHAR

Pharming Group (PHAR) Stock Price, News & Analysis

$10.17
0.00 (0.00%)
(As of 04/17/2024 ET)
Today's Range
$10.01
$10.55
50-Day Range
$10.00
$12.95
52-Week Range
$9.70
$16.71
Volume
9,820 shs
Average Volume
2,583 shs
Market Capitalization
$682.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00

Pharming Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
263.8% Upside
$37.00 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Pharming Group in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.02) to ($0.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

425th out of 913 stocks

Pharmaceutical Preparations Industry

178th out of 396 stocks

PHAR stock logo

About Pharming Group Stock (NASDAQ:PHAR)

Pharming Group N.V. is a Dutch biotech company specializing in developing innovative therapies for rare diseases. The company aims to improve patients' lives suffering from debilitating illnesses by developing and commercializing safe and effective treatments.

Pharming's lead product is Ruconest, a recombinant human C1 esterase inhibitor indicated for the treatment of hereditary angioedema (HAE) attacks. HAE is a rare and life-threatening genetic disorder that causes swelling in various body parts, including the hands, feet, face, and airways. Ruconest is the only recombinant C1 inhibitor approved by the FDA and EMA for the treatment of acute attacks of HAE in adults and adolescents.

The company's target market is patients suffering from HAE, which is estimated to affect approximately 1 in 10,000 to 1 in 50,000 people worldwide. The key customers for Ruconest are hospitals, clinics, and specialized treatment centers that provide care for patients with HAE.

Pharming is headquartered in Leiden, Netherlands, with additional offices in the United States and Switzerland. The company was founded in 1986 and went public on Euronext Amsterdam in 1999. In 2019, the company established a US subsidiary and started trading on the NASDAQ Global Market.

Pharming has achieved several key milestones in recent years. In 2019, the FDA approved Ruconest for treating acute attacks of HAE in pediatric patients, expanding the drug's market potential. In 2020, the company received a $10 million milestone payment from its partner, Kyowa Kirin, for the achievement of a sales target for Ruconest in Japan.

Sijmen de Vries is the Chief Executive Officer of Pharming and has been with the company since 2009. He has over 30 years of experience in the pharmaceutical industry, including leadership positions at Genzyme, AstraZeneca, and Schering-Plough.

Pharming reported revenue gradually increasing yearly over the past several years. The company's gross profit margin is around 80%, reflecting the high profitability of its products. Pharming has a manageable debt load with plenty of assets to cover liabilities. 

The company's revenue growth can be attributed to the strong performance of Ruconest, which generated sales of over $150 million a year for the past several years. The company also saw growth in its pipeline of products, with its new recombinant factor VIII product, RUCONEST® (human C1 esterase inhibitor) for treating acute HAE, receiving marketing authorization from the European Commission in 2021.

Pharming's valuation metrics are generally in line with its peers in the biotech industry. The company's price-to-earnings ratio is higher than the industry average. The company's price-to-book ratio is also higher than the industry average. These and other valuation metrics could mean investors see the stock as overvalued. 

The rare disease market is growing and lucrative, with an estimated 400 million worldwide suffering from rare diseases. The market for HAE treatments is expected to reach $2.7 billion by 2025, driven by the increasing prevalence of the disease and the introduction of new therapies.

Pharming faces competition from other biotech companies developing therapies for HAE, such as Takeda Pharmaceutical Company Limited and CSL Behring. However, Ruconest has demonstrated superior safety and efficacy compared to other C1 esterase inhibitors in clinical trials, giving the company a competitive advantage.

Pharming's pipeline includes promising products, such as RUCONEST® for treating acute HAE and Leniolisib for treating PIK3CA-related overgrowth spectrum (PROS). The company is also exploring new indications for Ruconest, such as treating pre-eclampsia and COVID-19.

Pharming has also recently announced plans to expand its manufacturing capacity with a new facility in the Netherlands. The new facility is expected to increase its production capacity and reduce reliance on third-party manufacturers, improving its gross margins and overall profitability.

The biotech industry is subject to regulatory and clinical risks, as the approval and commercialization of new products are dependent on regulatory agencies' decisions and successful clinical trials. Changes in reimbursement policies or the introduction of competing therapies could also impact the company's revenue growth.

Pharming also depends on the success of Ruconest, as it represents the majority of the company's revenue. Any unexpected safety concerns or competitive pressures could significantly impact the company's financial performance.

PHAR Stock Price History

PHAR Stock News Headlines

Pharming Group (NASDAQ:PHAR) Shares Gap Down to $11.30
Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
Pharming Group (NASDAQ:PHAR) Shares Gap Up to $10.00
Pharming Group (NASDAQ:PHAR) Short Interest Update
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
Pharming reports Q4 results
Pharming Group N.V. (PHGN.F)
Pharming Group issues full-year 2023 guidance
See More Headlines
Receive PHAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/17/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PHAR
Fax
N/A
Employees
332
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.00
High Stock Price Target
$37.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+263.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,550,000.00
Pretax Margin
-4.90%

Debt

Sales & Book Value

Annual Sales
$245.32 million
Cash Flow
$0.09 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
65,718,000
Market Cap
$682.51 million
Optionable
Not Optionable
Beta
0.16
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Sijmen de Vries M.B.A. (Age 65)
    M.D., President, CEO & Executive Director
    Comp: $1.18M
  • Mr. Jeroen Wakkerman (Age 55)
    Chief Financial Officer
  • Ms. Mireille Sanders M.Sc. (Age 56)
    Chief Operations Officer
  • Susanne Embleton
    Investor Relations Manager
  • Mr. Ruud Van Outersterp (Age 60)
    Chief Ethics & Compliance Officer
  • Dr. Anurag Relan M.D. (Age 52)
    MPH, Chief Medical Officer
  • Mr. Stephen Toor (Age 53)
    Chief Commercial Officer & GM Americas
  • Dr. Alexander Breidenbach M.B.A.
    Chief Business Officer
  • Dr. Bruno M. L. Giannetti (Age 72)
    Consultant

PHAR Stock Analysis - Frequently Asked Questions

Should I buy or sell Pharming Group stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHAR shares.
View PHAR analyst ratings
or view top-rated stocks.

What is Pharming Group's stock price target for 2024?

1 equities research analysts have issued 12 month price targets for Pharming Group's shares. Their PHAR share price targets range from $37.00 to $37.00. On average, they predict the company's share price to reach $37.00 in the next year. This suggests a possible upside of 263.8% from the stock's current price.
View analysts price targets for PHAR
or view top-rated stocks among Wall Street analysts.

How have PHAR shares performed in 2024?

Pharming Group's stock was trading at $11.43 at the start of the year. Since then, PHAR shares have decreased by 11.0% and is now trading at $10.17.
View the best growth stocks for 2024 here
.

Are investors shorting Pharming Group?

Pharming Group saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 1,500 shares, a decline of 44.4% from the March 15th total of 2,700 shares. Based on an average daily trading volume, of 2,400 shares, the short-interest ratio is presently 0.6 days.
View Pharming Group's Short Interest
.

When is Pharming Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PHAR earnings forecast
.

How were Pharming Group's earnings last quarter?

Pharming Group (NASDAQ:PHAR) posted its earnings results on Thursday, March, 14th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.08. The firm earned $81.20 million during the quarter, compared to the consensus estimate of $71.83 million. Pharming Group had a negative trailing twelve-month return on equity of 4.53% and a negative net margin of 4.13%.

How do I buy shares of Pharming Group?

Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHAR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners